Biocept Presents Robust Analytical Validation Study Results for its PD-L1 Liquid Biopsy Test at the 17th IASLC World Conference on Lung Cancer
In the study, introduced cell lines derived from multiple cancers were tested with
"Assessing PD-L1 status of a cancer patient has become increasingly important, as immuno-oncology treatments such as
The human immune system can recognize and eliminate tumor cells through immunosurveillance, however, certain cancer cell types suppress immune function by expressing programmed cell death ligand 1 (PD-L1), which binds to its receptor, PD-1, on T cells to prevent their activation. As a result, high levels of PD-L1 expression are associated with poor patient prognosis. Immunotherapies such as Keytruda ® and Opdivo® inhibit the PD-1/PD-L1 pathway and allow the body's natural defenses to combat the tumor. To determine which patients are suitable candidates for receiving immunotherapy, levels of PD-L1 expression are traditionally determined from tumor biopsies. However, the amount of tumor tissue or the variability in tumor tissue composition (tumor heterogeneity) can confound these results, creating the need for a non-invasive methodology for the identification and subsequent monitoring of tumor-associated PD-L1 expression.
"These data support the high sensitivity of our Target Selector™ platforms and our focus on providing clinically actionable information to oncologists and their patients based on a simple blood test," stated
"The presentation of these study results at a major cancer conference significantly increases our visibility with lung cancer specialists and further supports the use of our high performance liquid biopsy platform," said
About the
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the management, diagnosis and treatment of cancer, the ability of our
tests to provide clinically actionable information to oncologist and their patients, and our ability to expand the adoption of our tests, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
Logo - http://photos.prnewswire.com/prnh/20151013/276540LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocept-presents-robust-analytical-validation-study-results-for-its-pd-l1-liquid-biopsy-test-at-the-17th-iaslc-world-conference-on-lung-cancer-300374251.html
SOURCE
News Provided by Acquire Media